TSHA insider trading
HealthcareTaysha Gene Therapies, Inc.: insider trade history from SEC Form 4 filings.
About Taysha Gene Therapies, Inc.
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.
Company website: www.tayshagtx.com
TSHA insider activity at a glance
FilingIQ tracks 109 insider transactions for TSHA in filings since Sep 25, 2020. The most recent transaction is dated Jul 10, 2026.
Across the full history, 23 open-market purchases
and 43 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on TSHA insider trades is 55.6/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest TSHA Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Top insiders trading TSHA
Frequently asked
- How many insider trades does FilingIQ track for TSHA?
- FilingIQ tracks 109 Form 4 insider transactions for TSHA (Taysha Gene Therapies, Inc.), covering filings from Sep 25, 2020 onwards. 1 of those are dated within the last 90 days.
- Are TSHA insiders net buyers or net sellers?
- Across the full Form 4 history for TSHA, 23 transactions (21%) were open-market purchases and 43 (39%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does TSHA insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is TSHA in?
- Taysha Gene Therapies, Inc. (TSHA) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $1.25B.
Methodology & sources
Every TSHA insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.